Burrill Securities Acts as Exclusive Placement Agent for EntreMed $10.7 Million Registered Direct

Burrill Securities Acts as Exclusive Placement Agent for EntreMed $10.7 Million 
Registered Direct 
SAN FRANCISCO, CA -- (Marketwire) -- 03/01/13 --  EntreMed, Inc.
(NASDAQ: ENMD), a clinical-stage pharmaceutical company developing
therapeutics for the treatment of cancer, announced today that it has
received commitments from investors, including institutional
investors Kleiner Perkins Caufield Byers China Fund II, L.P. and
IDG-Accel China Growth Fund III L.P. to purchase approximately $10.7
million of securities in a registered direct offering. Burrill
Securities LLC acted as exclusive placement agent in this
transaction. 
"We are very pleased to have the support of this group of strategic
investors. We intend to use the net proceeds from this offering to
advance our clinical development plan, including additional trials
for ENMD-2076, and for general corporate purposes," said Dr. Ken Ren,
the Company's Chief Executive Officer. 
EntreMed is a clinical-stage pharmaceutical company developing
targeted therapeutics for the treatment of cancer and inflammatory
disease using a joint U.S.-China drug development model. EntreMed's
drug candidates target disease cells and the blood vessels that
nourish them. The company's goal is to develop and commercialize
therapeutic products based on its scientific expertise in
angiogenesis, cell signaling, cell cycle regulation, and inflammation
-- processes that are vital to the progression of cancer and other
diseases. 
"We are pleased to have the opportunity to work with EntreMed on this
transaction. Burrill Securities is focused on assisting exciting
healthcare companies reach their goals and deliver returns to their
shareholders," said Stephen Hurly, CEO Burrill Securities. "Whether
that means attracting capital, forging partnerships, or enabling
global M&A activity, we have the experience, global network, and
industry expertise to serve our clients."  
A shelf registration statement containing a prospectus relating to
the shares of common stock and warrants to be issued in this
transaction (and the shares of common stock issuable upon exercise of
the warrants) has been filed with the Securities and Exchange
Commission (the "SEC") and declared effective. A prospectus
supplement relating to the offering will be filed by EntreMed 
with
the SEC. Copies of the prospectus and prospectus supplement and
accompanying prospectuses may be obtained directly from Burrill
Securities LLC, Prospectus Department, One Embarcadero Center, Suite
2700, San Francisco, CA 94111, 415-591-5400 or email: wwang@b-c.com.
This announcement is neither an offer to sell nor a solicitation of
an offer to buy any securities of EntreMed. No offer, solicitation or
sale will be made in any jurisdiction in which such offer,
solicitation or sale is unlawful. 
About Burrill Securities LLC  
Burrill Securities provides life sciences companies with access to
financial resources through global capital and a complementary blend
of financial advisory services on public and private financings and
cross-border transactions, including M&A, strategic partnerships,
spinouts, and public and private capital raising. It provides
companies enhanced access to public market investors through its
Institutional Equities business. Our team has extensive experience
and a comprehensive global network to help life sciences companies
access capital and strategic partners to build their businesses.
Burrill Securities LLC, member FINRA/SIPC is the investment banking
arm of Burrill & Company. 
Contact:
Daniel Levine
Managing Director
Burrill & Company
dlevine@b-c.com
415-591-5449 
 
 
Press spacebar to pause and continue. Press esc to stop.